Current problems in cancer. Case reports最新文献_第2页

High-flow nasal cannula combined with intravenous general anesthesia for stent implantation in right lung cancer: A case report 高流量鼻插管联合静脉全身麻醉用于右肺癌支架植入术：病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-08-14 DOI: 10.1016/j.cpccr.2024.100319

{"title":"High-flow nasal cannula combined with intravenous general anesthesia for stent implantation in right lung cancer: A case report","authors":"","doi":"10.1016/j.cpccr.2024.100319","DOIUrl":"10.1016/j.cpccr.2024.100319","url":null,"abstract":"<div><p>Airway blockage frequently occurs in advanced lung cancer patients, leading to breathing difficulties and oxygen deprivation. This severely impacts patients' quality of life and can even result in death. Bronchial stent insertion effectively alleviates these symptoms and is often performed with intravenous general anesthesia. Nevertheless, during anesthesia and the procedure, inadequate ventilation can lead to severe oxygen deficiency and subsequent complications. There is an urgent need for a safe and efficient intraoperative ventilation strategy to maintain sufficient oxygen levels and reduce the risk of oxygen deficiency. We present a case of successful bronchial stent placement using high-flow nasal cannula (HFNC) in conjunction with intravenous general anesthesia. The patient, a 64-year-old male with a one-year history of right peripheral lung cancer, sought treatment for persistent cough and breathing difficulties. Chest X-rays upon admission revealed a substantial increase in the size of the anterior segment of the right upper lung lobe, likely due to peripheral lung cancer complicated by obstructive pneumonia. To address the patient's airway compression symptoms, we proposed \"bronchoscopic tracheal stent insertion.\" The patient exhibited an ejection fraction of 45% on cardiac ultrasound, had limited physical activity tolerance, grade III heart function, severe airway constriction, and maintained oxygen saturation (SPO<sub>2</sub>) levels between 85% and 88%. We successfully performed the procedure using HFNC in combination with intravenous general anesthesia, resulting in a significant improvement in airway compression symptoms. In this case, it was found that HFNC could be used as a new non-invasive respiratory support therapy for bronchial stent implantation under intravenous general anesthesia to reduce the occurrence of intraoperative hypoxemia.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000425/pdfft?md5=7d6234bff30fbabb67ea1b8c3511111e&pid=1-s2.0-S2666621924000425-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141998328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cutaneous toxicity following intra-arterial chemotherapy with melphalan for uveal melanoma: A case report 葡萄膜黑色素瘤动脉内美法仑化疗后的皮肤毒性：病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-08-08 DOI: 10.1016/j.cpccr.2024.100318

{"title":"Cutaneous toxicity following intra-arterial chemotherapy with melphalan for uveal melanoma: A case report","authors":"","doi":"10.1016/j.cpccr.2024.100318","DOIUrl":"10.1016/j.cpccr.2024.100318","url":null,"abstract":"<div><h3>Background</h3><p>This case report aims to describe an adverse reaction following intra-arterial melphalan chemotherapy in a 48-year-old female patient with choroidal melanoma. The chemotherapy was part of a phase I clinical trial (MELCOM Study - ClinicalTrials.gov ID: NCT05893654), designed to evaluate its efficacy as a bridge to Ru-106 brachytherapy for treating large uveal melanomas. This is the first reported case of a cutaneous reaction to melphalan in an adult patient.</p></div><div><h3>Observations</h3><p>Upon administration of melphalan, the patient developed an erythematous periorbital skin lesion three days post-treatment. The lesion evolved into a hyperchromic brownish macule that later disappeared spontaneously.</p></div><div><h3>Conclusions and Importance</h3><p>While melphalan successfully reduced the tumor dimensions, making the patient eligible for subsequent Ru-106 brachytherapy, it led to a cutaneous reaction previously reported only in pediatric patients. Despite this aesthetic complication, the therapy was effective in tumor reduction, highlighting the need for further studies to assess the risk-benefit profile of intra-arterial melphalan chemotherapy in adult populations.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000413/pdfft?md5=c96c3df08b57baf46f2ebade3beca62b&pid=1-s2.0-S2666621924000413-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141952539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disrupted care for multiple myeloma in an amenorrheic woman due to a false-positive pregnancy test: A case report 因妊娠试验假阳性而中断对一名停经妇女的多发性骨髓瘤治疗：病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-07-30 DOI: 10.1016/j.cpccr.2024.100316

{"title":"Disrupted care for multiple myeloma in an amenorrheic woman due to a false-positive pregnancy test: A case report","authors":"","doi":"10.1016/j.cpccr.2024.100316","DOIUrl":"10.1016/j.cpccr.2024.100316","url":null,"abstract":"<div><p>We report the case of a 48-year-old female with a history of tubal ligation who presented to her PCP with altered mental status and back pain. Inpatient workup revealed multiple myeloma, and treatment with bortezomib and dexamethasone was initiated. Due to teratogenicity on lenalidomide, a pre-treatment urine pregnancy test was performed and returned positive. She denied sexual activity and had no history of germ cell tumor. While urine hCG remained low positive for three tests, her serum hCG remained normal (<5 mIU/mL). The uncertainty in pregnancy testing caused a delay in full-dose induction therapy. With two cycles of bortezomib and dexamethasone, her M-Spike only dropped from 4.8 to 2.9 g/dL. Ultimately urine hCG normalized, and she was started on lenalidomide with cycle number three. With the addition of lenalidomide, after two cycles, her M-Spike disappeared, and bone marrow biopsy showed complete resolution of plasma cell dyscrasia. The phenomenon of positive hCG testing in multiple myeloma is discussed, highlighting the importance of provider and patient awareness in the setting of a non-gravid woman to prevent a disruption of standard of care treatment and patient distress.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000395/pdfft?md5=58903e12d97434ddec5c0757131a70e9&pid=1-s2.0-S2666621924000395-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141950832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges in managing extensive brown tumors and renal stones in a young man with parathyroid carcinoma and single kidney: Case report 治疗一名患有甲状旁腺癌和单肾的年轻人的广泛性褐色肿瘤和肾结石的挑战：病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-07-25 DOI: 10.1016/j.cpccr.2024.100317

{"title":"Challenges in managing extensive brown tumors and renal stones in a young man with parathyroid carcinoma and single kidney: Case report","authors":"","doi":"10.1016/j.cpccr.2024.100317","DOIUrl":"10.1016/j.cpccr.2024.100317","url":null,"abstract":"<div><p>Parathyroid carcinoma is one of the rare causes of primary hyperparathyroidism, comprising less than 1 % of its cases. Diagnosing parathyroid carcinoma typically requires a comprehensive evaluation using clinical, histological, and radiological methods. Primary hyperparathyroidism secondary to parathyroid carcinoma often presents with hypercalcemia, bone abnormalities, and renal stones. Brown tumours, a rare and late manifestation of hyperparathyroidism, signify the final stage in bone remodelling, and they can be easily mistaken for bony metastases, which highlights the importance of distinguishing between them to ensure appropriate management and avoid unnecessary treatment. Due to the rarity of parathyroid carcinoma, there is currently no standardized staging system or specific guidelines for its management. Consequently, the involvement of a multidisciplinary team has become crucial in addressing this disease. Surgery is considered the primary treatment approach, while the role of adjuvant radiotherapy and chemotherapy remains controversial. With ongoing research, the treatment landscape for parathyroid carcinoma may evolve, offering new hope for improved outcomes and quality of life for affected individuals.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000401/pdfft?md5=1cafb0bcb3d935da3042c1c835ac3d90&pid=1-s2.0-S2666621924000401-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141848086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lenvatinib in combination with pembrolizumab in heavily pretreated metastatic thymic carcinoma: A case report 伦伐替尼联合 Pembrolizumab 治疗重度预处理转移性胸腺癌：病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-07-23 DOI: 10.1016/j.cpccr.2024.100315

{"title":"Lenvatinib in combination with pembrolizumab in heavily pretreated metastatic thymic carcinoma: A case report","authors":"","doi":"10.1016/j.cpccr.2024.100315","DOIUrl":"10.1016/j.cpccr.2024.100315","url":null,"abstract":"<div><p>Thymoma and thymic carcinomas are rare tumors with limited therapeutic options for platinum-refractory cases. Recent studies have shown positive response rates in anti-angiogenic multi-kinase inhibitors (MKI) such as lenvatinib and sunitinib and immune checkpoint inhibitors including pembrolizumab, though they have yet to be tested in combination. Here, we present a case of a patient with heavily pre-treated PD-L1 negative metastatic thymic carcinoma and no targetable mutations treated with combination lenvatinib and pembrolizumab following initial response then progression from lenvatinib monotherapy. He had a partial response with decreased tumor burden in the liver with lenvatinib monotherapy and then in the lungs with combination therapy. Treatment was continued and he continues have clinical benefit with stable disease at 9 months with minimal toxicities. This case is one of the first reported clinical evidence for MKI and immunotherapy in combination as a promising second-line approach for thymic carcinomas.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000383/pdfft?md5=7d4e4649bddd9dc1a0f480ca54db15cb&pid=1-s2.0-S2666621924000383-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metachronous bilateral invasive breast carcinoma with low-grade adenosquamous carcinoma on one side: A case report and literature review 双侧浸润性乳腺癌并发一侧低级别腺鳞癌：病例报告和文献综述

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-07-14 DOI: 10.1016/j.cpccr.2024.100314

{"title":"Metachronous bilateral invasive breast carcinoma with low-grade adenosquamous carcinoma on one side: A case report and literature review","authors":"","doi":"10.1016/j.cpccr.2024.100314","DOIUrl":"10.1016/j.cpccr.2024.100314","url":null,"abstract":"<div><p>Low-grade adenosquamous carcinoma (LGASC) is a rare variant of metaplastic breast carcinoma that consists of glandular and squamous elements in a spindle cell background. They lack distinctive imaging features and overlap with other breast neoplasm characteristics, posing a diagnostic challenge. We present the case of a 60-year-old woman with metachronous bilateral invasive breast carcinoma (MBBC). The mastectomy specimens of her left breast carcinoma revealed nests of squamous- appearing cells and “comma” glandular structures on a microscopic level. Comprehensive immunohistochemical examination of ER, PR, Her-2, p63, and CK7 CK5/6 confirmed the diagnosis of LGASC. Unlike other invasive breast carcinomas, LGASC have an indolent course and favorable prognosis. Eight years after surgery, she was diagnosed with a non-specific type of invasive breast carcinoma of the right breast via imaging, core needle biopsy and immunohistochemistry. This was a rare case of MBBC that has not been previously reported. Therefore, we report and review the relevant literature to raise awareness of this disease.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000371/pdfft?md5=57299d840d6ad866067bf5fe9ba7777e&pid=1-s2.0-S2666621924000371-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141623675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acquired pachydermatoglyphia: An ominous sign, two case reports 后天性畸形：一种不祥的征兆，两份病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-07-06 DOI: 10.1016/j.cpccr.2024.100312

引用次数: 0

Epitheliotropic monomorphic intestinal T cell lymphoma: Case report and literature review 上皮细胞性单形性肠 T 细胞淋巴瘤：病例报告和文献综述

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-07-05 DOI: 10.1016/j.cpccr.2024.100313

引用次数: 0

Adenoid cystic carcinoma of the breast–A case report and review of the literature 乳腺腺样囊性癌--病例报告和文献综述

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-06-30 DOI: 10.1016/j.cpccr.2024.100309

引用次数: 0

Cryoablation as the primary treatment in a HER2 positive Stage IV breast cancer patient: 5 years term follow up case report 将冷冻消融作为 HER2 阳性 IV 期乳腺癌患者的主要治疗方法：5 年随访病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-06-22 DOI: 10.1016/j.cpccr.2024.100311

Kizuki Matsumoto , Masaaki Sakamoto , Youichi Machida , Masafumi Kurosumi , Eisuke Fukuma

{"title":"Cryoablation as the primary treatment in a HER2 positive Stage IV breast cancer patient: 5 years term follow up case report","authors":"Kizuki Matsumoto , Masaaki Sakamoto , Youichi Machida , Masafumi Kurosumi , Eisuke Fukuma","doi":"10.1016/j.cpccr.2024.100311","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100311","url":null,"abstract":"<div><p>We report a case of human epidermal growth factor receptor 2 (HER2)-positive Stage IV breast cancer with metastatic lung cancer treated with cryoablation as a first-line treatment. The patient, a 34-year-old woman who voluntarily screened for breast cancer, was referred to our clinic after a mammogram revealed calcification findings. The patient had a tumor in the right breast and lung metastasis. The tumor was 34×31×23 mm with internal heterogeneity in the right mammary gland. Imaging and vacuum-assisted breast tumor biopsy led to a diagnosis of invasive ductal carcinoma (estrogen receptor-positive, progesterone receptor-negative, and human epidermal growth factor receptor 2 positive). The patient received 6 cycles of trastuzumab, and paclitaxel, followed by 11 cycles of trastuzumab, pertuzumab and tamoxifen as pre-cryoablation adjuvant therapy. After chemotherapy, the patient underwent minimally invasive cryoablation treatment followed by fractionated radiation therapy to the entire right breast.</p><p>In the last follow-up, 5 years following cryoablation as a first-line treatment after anti-HER2 therapy, a complete local response was recognized, with no evidence of disease progression in the lung metastasis or recurrence of the primary breast tumor. This case report demonstrates that cryoablation is safe and effective, with favorable cosmetic results also for late-stage breast cancer.</p><p>Cryoablation, as a minimally invasive treatment for primary site control of Stage IV breast cancer, can provide a good alternative that preserves the quality of life. It can be performed under local anesthesia and be conducted jointly with chemotherapy, radiation therapy, surgery, and immunotherapy.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000346/pdfft?md5=76320a9fadc67748a0ce414ae5dd80e7&pid=1-s2.0-S2666621924000346-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141541333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0